Download Full Text (390 KB)
• Lowering low-density lipoprotein cholesterol (LDL-C) concentration in the population has been a goal of researchers and clinicians to prevent atherosclerotic cardiovascular disease (ASCVD).
• Controversy surrounds using [LDL-C] as the primary lipid biomarker to evaluate the risk of cardiovascular events. An article search dating back to 2005 of PubMed and The Cochran Library was conducted.
• The purpose of this investigation was to determine if LDL-C should be the primary lipid biomarker used to determine ASCVD treatment and prevention. This investigation researched other lipid biomarkers and targets to determine clinical relevance and if the level of those markers more accurately represents ASCVD in adults 21-75 years of age not afflicted by other chronic diseases.
• It was found that both non-high-density lipoprotein cholesterol (non-HDL-C) and apolipoprotein B (apoB) both better represent ASCVD risk than LDL-C, with apoBbeing superior to non-HDL-C.
Physician Assistant Studies
Master of Physician Assistant Studies (MPAS)
Apolipoproteins B -- blood; Biomarkers -- blood; Cardiovascular Diseases -- diagnosis; Cholesterol, HDL -- blood; Cholesterol, LDL -- blood; Predictive Value of Tests; Risk Factors; Comparative Study
Coauette, Grant, "Non-HDL-C or Apolipoprotein-B versus LDL-C Screening for Evaluation and Treatment of Atherosclerotic Cardiovascular Disease" (2016). Physician Assistant Scholarly Project Posters. 66.